Cluster of hemolytic-uremic syndrome caused by Shiga toxin-producing Escherichia coli O26:H11

Background. The epidemiology and clinical characteristics of the hemolytic-uremic syndrome (HUS) caused by Escherichia coli O157:H7 are well-known, but HUS attributable to non-O157:H7 Shiga toxin (Stx)-producing E. coli (STEC) are less thoroughly described. Here we report a cluster of HUS cases caused by STEC O26:H11 the most common non-O157:H7 STEC isolated from sporadic cases of HUS in Europe. Methods. Three children between 13 and 17 months of age, living in the same small town, developed HUS within an interval of 5 days. We present clinical and microbiologic data on the patients and their infecting isolates. Results. The clinical course ranged from mild uncomplicated HUS to severe HUS complicated by multiorgan involvement. Microbiologic investigation demonstrated STEC of serotype O26:H11 in stools of all the patients. The phenotypic and molecular characterization of the STEC O26:H11 isolates demonstrated that these strains were identical and, unusual for STEC O26, they harbored the stx2 but not the stx1 gene. None of the patients had evidence of STEC O157:H7 infection either by culture or by E. coli O157 serology. The source of the STEC O26:H11 infection was undetermined. Conclusions. Our results demonstrate that diagnostic procedures based on the detection of stx genes and/or Stx production and subsequent subtyping of the isolates using molecular methods are necessary to identify such outbreaks caused by non-O157:H7 STEC.

[1]  J. Janda,et al.  Vero cytotoxin-producing strains of Escherichia coli in children with haemolytic uraemic syndrome and diarrhoea in Czechoslovakia , 1990, Infection.

[2]  C. Bréchot,et al.  Immunomodulatory drugs and therapeutic vaccine in chronic hepatitis B infection. , 2003, Journal of hepatology.

[3]  B. Dikici,et al.  Combination therapy for children with chronic hepatitis B virus infection , 2002, Journal of gastroenterology and hepatology.

[4]  J. Bockemühl,et al.  Infektionen des Menschen durch enterohämorrhagische Escherichia coli (EHEC) in der Bundesrepublik Deutschland von 1998 bis 2001 Prävalenz und Typenspektrum , 2002, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.

[5]  N. Okamura,et al.  Epidemiol. Infect. 127 (2001), 221–7 An outbreak of diarrhoea due to multiple antimicrobial-resistant Shiga toxin-producing Escherichia coli O26: H11 in a nursery , 2002, Epidemiology and Infection.

[6]  N. Okamura,et al.  An outbreak of diarrhoea due to multiple antimicrobial-resistant Shiga toxin-producing Escherichia coli O26[ratio ]H11 in a nursery , 2001, Epidemiology and Infection.

[7]  B. Dikici,et al.  Lamivudine and interferon-alpha combination treatment of childhood patients with chronic hepatitis B infection. , 2001, The Pediatric infectious disease journal.

[8]  D. V. van Thiel,et al.  Increased effective immunogenicity to high‐dose and short‐interval hepatitis B virus vaccination in individuals with chronic hepatitis without cirrhosis , 2001, Journal of viral hepatitis.

[9]  A. Siitonen,et al.  Clinical Isolates of Non-O157 Shiga Toxin-ProducingEscherichia coli: Serotypes, Virulence Characteristics, and Molecular Profiles of Strains of the Same Serotype , 2001, Journal of Clinical Microbiology.

[10]  C. Bréchot,et al.  Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. , 2001, Journal of hepatology.

[11]  T. Cheasty,et al.  Verocytotoxin-Producing Escherichia coli Serotype O26 : H11 Outbreak in an Irish Crèche , 2001, European Journal of Clinical Microbiology and Infectious Diseases.

[12]  G. Ogg,et al.  Lamivudine treatment can overcome cytotoxic T‐cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy , 2001, Hepatology.

[13]  J. H. Green,et al.  The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings. , 2001, The Journal of infectious diseases.

[14]  C. Bréchot,et al.  Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future. , 2001, Vaccine.

[15]  H. Karch,et al.  Non-O157:H7 Shiga toxin (verocytotoxin)-producing Escherichia coli strains: epidemiological significance and microbiological diagnosis , 2000 .

[16]  A. Caprioli,et al.  Typing of Intimin Genes in Human and Animal Enterohemorrhagic and Enteropathogenic Escherichia coli: Characterization of a New Intimin Variant , 2000, Infection and Immunity.

[17]  H. Karch,et al.  Molecular characteristics and epidemiological significance of Shiga toxin-producing Escherichia coli O26 strains. , 2000, Journal of clinical microbiology.

[18]  H. Karch,et al.  Epidemiology and diagnosis of Shiga toxin-producing Escherichia coli infections. , 1999, Diagnostic microbiology and infectious disease.

[19]  C. Bréchot,et al.  Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. , 1999, The Journal of infectious diseases.

[20]  F. Mahoney,et al.  Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection , 1999, Clinical Microbiology Reviews.

[21]  T. Kawakita,et al.  Epidemic of Gastrointestinal Tract Infection Including Hemorrhagic Colitis Attributable to Shiga Toxin 1-producingEscherichia coli O118:H2 at a Junior High School in Japan , 1999, Pediatrics.

[22]  A. Bertoletti,et al.  Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. , 1998, The Journal of clinical investigation.

[23]  E. Avner,et al.  Cholelithiasis following Escherichia coli O157 : H7-associated hemolytic uremic syndrome , 1998, Pediatric Nephrology.

[24]  H. Karch,et al.  Shiga Toxin-Producing Escherichia coli Infections in Germany †. , 1997, Journal of food protection.

[25]  H. Karch,et al.  EspP, a novel extracellular serine protease of enterohaemorrhagic Escherichia coli O157:H7 cleaves human coagulation factor V , 1997, Molecular microbiology.

[26]  H. Karch,et al.  A gene cluster closely related to type II secretion pathway operons of gram-negative bacteria is located on the large plasmid of enterohemorrhagic Escherichia coli O157 strains. , 1997, FEMS microbiology letters.

[27]  I. Capek,et al.  Possible person-to-person transmission of Escherichia coli O111 – associated hemolytic uremic syndrome , 1997, Pediatric Nephrology.

[28]  J. H. Green,et al.  Shiga-like toxin-producing Escherichia coli O111 and associated hemolytic-uremic syndrome: a family outbreak. , 1996, The Pediatric infectious disease journal.

[29]  H. Karch,et al.  KatP, a novel catalase-peroxidase encoded by the large plasmid of enterohaemorrhagic Escherichia coli O157:H7. , 1996, Microbiology.

[30]  J. Lanser,et al.  Molecular microbiological investigation of an outbreak of hemolytic-uremic syndrome caused by dry fermented sausage contaminated with Shiga-like toxin-producing Escherichia coli , 1996, Journal of clinical microbiology.

[31]  J. Janda,et al.  Verocytotoxin-producing Escherichia coli in children with hemolytic uremic syndrome in the Czech Republic. , 1996, Clinical nephrology.

[32]  J. Blanco,et al.  Brote de gastroenteritis asociado con un Escherichia coli verotoxigénico (ECVT) O111:H-VT1+ eae+ , 1996 .

[33]  L. Beutin,et al.  Molecular analysis of the plasmid-encoded hemolysin of Escherichia coli O157:H7 strain EDL 933 , 1995, Infection and immunity.

[34]  W. L. Payne,et al.  Simultaneous identification of strains of Escherichia coli serotype O157:H7 and their Shiga-like toxin type by mismatch amplification mutation assay-multiplex PCR , 1995, Journal of clinical microbiology.

[35]  F. Chisari,et al.  Hepatitis B virus immunopathogenesis. , 1995, Annual review of immunology.

[36]  R. L. Guerrant,et al.  Escherichia coli O157:H7. , 1995, The New England journal of medicine.

[37]  A. Vitiello,et al.  Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. , 1995, The Journal of clinical investigation.

[38]  Serotype O104H Outbreak of acute gastroenteritis attributable to Escherichia coli serotype O104:H21--Helena, Montana, 1994. , 1995, MMWR. Morbidity and mortality weekly report.

[39]  H. Karch,et al.  Prevalence of attaching and effacing Escherichia coli in stool samples from patients and controls. , 1994, Zentralblatt fur Bakteriologie : international journal of medical microbiology.

[40]  A. Edefonti,et al.  Communitywide Outbreak of Hemolytic-Uremic Syndrome Associated with Non-O157 Verocytotoxin-Producing Escherichia coli , 1994 .

[41]  A. Edefonti,et al.  Community-wide outbreak of hemolytic-uremic syndrome associated with non-O157 verocytotoxin-producing Escherichia coli. , 1994, The Journal of infectious diseases.

[42]  A. Lok,et al.  Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. , 1993, Gastroenterology.

[43]  I. Lauder,et al.  A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. , 1992, Gastroenterology.

[44]  H. Karch,et al.  Indirect hemagglutination assay for diagnosis of Escherichia coli O157 infection in patients with hemolytic-uremic syndrome , 1992, Journal of clinical microbiology.

[45]  U. Spengler,et al.  Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. , 1991, Journal of hepatology.

[46]  H. Suzuki [Treatment of hepatitis B]. , 1990, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

[47]  A. Lok,et al.  Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children. , 1987, Lancet.

[48]  H. Lior,et al.  The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. , 1985, The Journal of infectious diseases.

[49]  J. Wells,et al.  Hemorrhagic colitis associated with a rare Escherichia coli serotype. , 1983, The New England journal of medicine.

[50]  M. Petric,et al.  SPORADIC CASES OF HAEMOLYTIC-URAEMIC SYNDROME ASSOCIATED WITH FAECAL CYTOTOXIN AND CYTOTOXIN-PRODUCING ESCHERICHIA COLI IN STOOLS , 1983, The Lancet.

[51]  R. Fieve,et al.  Letter: How blind is the double-blind?: an assessment in a lithium-prophylaxis study. , 1974, Lancet.

[52]  S. Cutillo [Hemolytic-uremic syndrome]. , 1973, La Pediatria.